New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology

References

• Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–1989. doi: 10.1136/annrheumdis-2014-205375
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Huddleston Slater JJR, et al. Health-related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology (Oxford). 2009;48(9):1077–1082. doi: 10.1093/rheumatology/kep141
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Restrepo Vélez J, Baldini C, et al. Comorbidities (excluding lymphoma) in Sjögren’s syndrome. Rheumatology (Oxford). 2021;60(5):2075–2084. doi: 10.1093/rheumatology/key329
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjögren’s syndrome. The Lancet. 2005;366(9482):321–331. doi: 10.1016/S0140-6736(05)66990-5
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2(1):1–20. doi: 10.1038/nrdp.2016.47
   Google Scholar
• Zhong H, Liu S, Wang Y, et al. Primary Sjögren’s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev. 2022;21:103084. doi: 10.1016/j.autrev.2022.103084
   PubMed Web of Science ®Google Scholar
• Bowman SJ, St Pierre Y, Sutcliffe N, et al. Estimating indirect costs in primary Sjögren’s syndrome. J Rheumatol. 2010;37(5):1010–1015. doi: 10.3899/jrheum.090734
   PubMed Web of Science ®Google Scholar
• Callaghan R, Prabu A, Allan RB, et al. Direct healthcare costs and predictors of costs in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46(1):105–111. doi: 10.1093/rheumatology/kel155
   PubMed Web of Science ®Google Scholar
• Costa T, Rushton SP, Watson S, et al. Depression in Sjögren’s syndrome mediates the relationship between pain, fatigue, sleepiness, and overall quality of life. Rheumatol Immunol Res. 2023;4(2):78–89. doi: 10.2478/rir-2023-0012
   PubMedGoogle Scholar
• Cornec D, Jamin C, Pers J-O. Sjögren’s syndrome: where do we stand, and where shall we go? J Autoimmun. 2014;51:109–114. doi: 10.1016/j.jaut.2014.02.006
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheumatic Dis. 2020;79(1):3–18. doi: 10.1136/annrheumdis-2019-216114
   PubMed Web of Science ®Google Scholar
• Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren syndrome. Nat Rev Rheumatol. 2021;17(8):475–486. doi: 10.1038/s41584-021-00634-x
   PubMed Web of Science ®Google Scholar
• Rose NR, Herskowitz A, Neumann DA, et al. Autoimmune myocarditis: a paradigm of post-infection autoimmune disease. Immunol Today. 1988;9(4):117–120. doi: 10.1016/0167-5699(88)91282-0
   PubMedGoogle Scholar
• Rose NR. Infection, mimics, and autoimmune disease. J Clin Invest. 2001;107(8):943–944. doi: 10.1172/JCI12673
   PubMed Web of Science ®Google Scholar
• Barnaba V, Sinigaglia F. Molecular mimicry and T cell–mediated autoimmune disease. J Exp Med. 1997;185(9):1529–1532. doi: 10.1084/jem.185.9.1529
   PubMed Web of Science ®Google Scholar
• Kuo C-F, Grainge MJ, Valdes AM, et al. Familial risk of Sjögren’s syndrome and Co-aggregation of autoimmune diseases in affected families: a nationwide population study. Arthritis & rheumat. 2015;67(7):1904–1912. doi: 10.1002/art.39127
   PubMed Web of Science ®Google Scholar
• Thorlacius GE, Björk A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023;19(5):288–306. doi: 10.1038/s41584-023-00932-6
   PubMed Web of Science ®Google Scholar
• Thorlacius GE, Hultin-Rosenberg L, Sandling JK, et al. Genetic and clinical basis for two distinct subtypes of primary Sjögren’s syndrome. Rheumatology (Oxford). 2021;60(2):837–848. doi: 10.1093/rheumatology/keaa367
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang K, Chen H, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren’s syndrome at 7q11.23. Nat Genet. 2013;45(11):1361–1365. doi: 10.1038/ng.2779
   PubMed Web of Science ®Google Scholar
• Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat Genet. 2013;45(11):1284–1292. doi: 10.1038/ng.2792
   PubMed Web of Science ®Google Scholar
• Mentlein L, Thorlacius GE, Meneghel L, et al. The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages. Clin Exp Immunol. 2018;193(2):167–177. doi: 10.1111/cei.13138
   PubMed Web of Science ®Google Scholar
• Aqrawi LA, Ivanchenko M, Björk A, et al. Diminished CXCR5 expression in peripheral blood of patients with Sjögren’s syndrome may relate to both genotype and salivary gland homing. Clin Exp Immunol. 2018;192(3):259–270. doi: 10.1111/cei.13118
   PubMed Web of Science ®Google Scholar
• Bodewes ILA, Björk A, Versnel MA, et al. Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome. Rheumatology. 2021;60(6):2561–2573. doi: 10.1093/rheumatology/key360
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Gestermann N, Ittah M, et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren’s syndrome. Arthritis Rheum. 2009;60(7):1991–1997. doi: 10.1002/art.24662
   PubMedGoogle Scholar
• Gestermann N, Mekinian A, Comets E, et al. STAT4 is a confirmed genetic risk factor for Sjögren’s syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun. 2010;11(5):432–438. doi: 10.1038/gene.2010.29
   PubMed Web of Science ®Google Scholar
• Tsinti M, Kassi E, Korkolopoulou P, et al. Functional estrogen receptors alpha and beta are expressed in normal human salivary gland epithelium and apparently mediate immunomodulatory effects. Eur J Oral Sci. 2009;117(5):498–505. doi: 10.1111/j.1600-0722.2009.00659.x
   PubMed Web of Science ®Google Scholar
• Ishimaru N, Arakaki R, Yoshida S, et al. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren’s syndrome–like autoimmune exocrinopathy. J Exp Med. 2008;205(12):2915–2927. doi: 10.1084/jem.20080174
   PubMed Web of Science ®Google Scholar
• Rizzo C, Grasso G, Destro Castaniti GM, et al. Primary Sjogren syndrome: focus on innate immune cells and inflammation. Vaccines. 2020;8(2):272. doi: 10.3390/vaccines8020272
   Web of Science ®Google Scholar
• You R, He X, Zeng Z, et al. Pyroptosis and its role in autoimmune disease: a potential therapeutic target. Front Immunol. [Internet]. 2022;13. [cited 2023 Oct 3]. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.841732
   Web of Science ®Google Scholar
• Vakrakou AG, Boiu S, Ziakas PD, et al. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjögren’s syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. 2018;91:23–33. doi: 10.1016/j.jaut.2018.02.010
   PubMed Web of Science ®Google Scholar
• Vakrakou AG, Svolaki IP, Evangelou K, et al. Cell-autonomous epithelial activation of AIM2 (absent in melanoma-2) inflammasome by cytoplasmic DNA accumulations in primary Sjögren’s syndrome. J Autoimmun. 2020;108:102381. doi: 10.1016/j.jaut.2019.102381
   PubMed Web of Science ®Google Scholar
• Hong S-M, Lee J, Jang SG, et al. Type I interferon increases inflammasomes associated pyroptosis in the salivary glands of patients with primary Sjögren’s syndrome. Immune Netw. 2020;20:e39. doi: 10.4110/in.2020.20.e39
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol. 2008;67(2):185–192. doi: 10.1111/j.1365-3083.2007.02049.x
   PubMed Web of Science ®Google Scholar
• Pers J-O, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56(5):1464–1477. doi: 10.1002/art.22603
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome. Arthritis Res Ther Internet. 2006;8 (2):R51. [cited 2023 Sep 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/16507175/
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Gottenberg J-E, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol. 2008;38(4):1058–1064. doi: 10.1002/eji.200738013
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62(2):168–171. doi: 10.1136/ard.62.2.168
   PubMed Web of Science ®Google Scholar
• Nocturne G, Pontarini E, Bombardieri M, et al. Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford). 2021;60(8):3513–3521. doi: 10.1093/rheumatology/kez052
   PubMed Web of Science ®Google Scholar
• Hong X, Meng S, Tang D, et al. Single-cell RNA sequencing reveals the expansion of cytotoxic CD4+ T lymphocytes and a landscape of immune cells in primary Sjögren’s syndrome. Front Immunol [Internet]. 2021;11. [cited 2023 Oct 1]. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2020.594658
   Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–162. doi: 10.1016/j.immuni.2011.02.012
   PubMed Web of Science ®Google Scholar
• Maehara T, Moriyama M, Hayashida J-N, et al. Selective localization of T helper subsets in labial salivary glands from primary Sjögren’s syndrome patients. Clin Exp Immunol. 2012;169(2):89–99. doi: 10.1111/j.1365-2249.2012.04606.x
   PubMed Web of Science ®Google Scholar
• Pontarini E, Murray-Brown WJ, Croia C, et al. Unique expansion of IL-21+ tfh and tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma. Ann Rheum Dis. 2020;79(12):1588–1599. doi: 10.1136/annrheumdis-2020-217646
   PubMed Web of Science ®Google Scholar
• Lin X, Wang X, Xiao F, et al. IL-10-producing regulatory B cells restrain the T follicular helper cell response in primary Sjögren’s syndrome. Cell Mol Immunol. 2019;16(12):921–931. doi: 10.1038/s41423-019-0227-z
   PubMed Web of Science ®Google Scholar
• Sarigul M, Yazisiz V, Bassorgun CI, et al. The numbers of Foxp3+ Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren’s syndrome. Lupus. 2010;19(2):138–145. doi: 10.1177/0961203309348234
   PubMed Web of Science ®Google Scholar
• Psianou K, Panagoulias I, Papanastasiou AD, et al. Clinical and immunological parameters of Sjögren’s syndrome. Autoimmun Rev. 2018;17:1053–1064. doi: 10.1016/j.autrev.2018.05.005
   PubMed Web of Science ®Google Scholar
• Pontarini E, Verstappen GM, Grigoriadou S, et al. Blocking T cell co-stimulation in primary Sjögren’s syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. Clin Exp Rheumatol. 2020;38(Suppl 126):222–227.
   PubMedGoogle Scholar
• Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–603. doi: 10.1126/science.1202947
   PubMed Web of Science ®Google Scholar
• van Berkel, MEAT, Oosterwegel MA. CD28 and ICOS: similar or separate costimulators of T cells? Immunol Lett. 2006;105(2):115–122. doi: 10.1016/j.imlet.2006.02.007
   PubMed Web of Science ®Google Scholar
• Wieczorek G, Bigaud M, Pfister S, et al. Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome. Ann Rheumatic Dis. 2019;78(7):974–978. doi: 10.1136/annrheumdis-2018-213929
   PubMed Web of Science ®Google Scholar
• Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2013;9(9):544–556. doi: 10.1038/nrrheum.2013.110
   PubMed Web of Science ®Google Scholar
• Amft N, Curnow SJ, Scheel-Toellner D, et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren’s syndrome. Arthritis Rheum. 2001;44(11):2633–2641. doi: 10.1002/1529-0131(200111)44:11<2633:AID-ART443>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjogren’s syndrome: an overview. J Autoimmun. 2012;39(4):354–358. doi: 10.1016/j.jaut.2012.05.011
   PubMed Web of Science ®Google Scholar
• Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, et al. Hypofunction of the stress axis in Sjögren’s syndrome. J Rheumatol. 1998;25:1508–1514.
   PubMed Web of Science ®Google Scholar
• Johnson EO, Kostandi M, Moutsopoulos HM. Hypothalamic-pituitary-adrenal axis function in Sjögren’s syndrome. Ann N Y Acad Sci. 2006;1088(1):41–51. doi: 10.1196/annals.1366.018
   PubMedGoogle Scholar
• Fox RI, Stern M. Sjögren’s syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl. 2002;116(sup116):3–13. doi: 10.1080/0300974023208178882
   PubMedGoogle Scholar
• Posada J, Valadkhan S, Burge D, et al. Improvement of severe fatigue following nuclease therapy in patients with primary Sjögren’s syndrome: a randomized clinical trial. Arthritis & Rheumat. 2021;73(1):143–150. doi: 10.1002/art.41489
   PubMed Web of Science ®Google Scholar
• Howard Tripp N, Tarn J, Natasari A, et al. Fatigue in primary Sjögren’s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open. 2016;2(2):e000282. doi: 10.1136/rmdopen-2016-000282
   PubMedGoogle Scholar
• Davies K, Mirza K, Tarn J, et al. Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int. 2019;39(11):1867–1873. doi: 10.1007/s00296-019-04354-0
   PubMed Web of Science ®Google Scholar
• Price E, Bombardieri M, Kivitz A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology. 2022;61(12):4797–4808. doi: 10.1093/rheumatology/keac167
   PubMed Web of Science ®Google Scholar
• Bai W, Liu H, Dou L. Pilot study of baricitinib for active Sjogren’s syndrome. Ann Rheumatic Dis. 2022;81(7):1050–1052. doi: 10.1136/annrheumdis-2021-222053
   PubMed Web of Science ®Google Scholar
• Kang EH, Lee YJ, Hyon JY, et al. Salivary cytokine profiles in primary Sjögren’s syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol. 2011;29:970–976.
   PubMed Web of Science ®Google Scholar
• Chatzantoni K, Mouzaki A. Anti-TNF-α Antibody Therapies in Autoimmune Diseases. Current Topics In Medicinal Chemistry [Internet]. 2006;6 (16):1707–1714. [cited 2023 Oct 3]. Available from: https://pubmed.ncbi.nlm.nih.gov/17017952/
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis & Rheumatism. 2004;50(7):2240–2245. doi: 10.1002/art.20299
   PubMedGoogle Scholar
• Zandbelt MM, de WP, van DP, et al. Etanercept in the treatment of patients with primary Sjögren’s syndrome: a pilot study. J Rheumatol. 2004;31:96–101. 1
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis & Rheumatism. 2004;50(4):1270–1276. doi: 10.1002/art.20146
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“infliximab in patients with primary Sjögren’s syndrome: a pilot study” and “infliximab in patients with primary Sjögren’s syndrome: one-year followup”). Arthritis Rheum. 2013;65(3):814. doi: 10.1002/art.37874
   PubMedGoogle Scholar
• Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor and systemic immune activation. Ann Rheumatic Dis. 2008;67(10):1437–1443. doi: 10.1136/ard.2007.077891
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon‐α pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis & Rheumatism. 2007;56:3995–4004. doi: 10.1002/art.23062
   PubMed Web of Science ®Google Scholar
• Aderka D, Engelmann H, Wysenbeek AJ, et al. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci. 1992;28(2):126–130.
   PubMedGoogle Scholar
• North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82(4):1013–1067. doi: 10.1152/physrev.00015.2002
   PubMed Web of Science ®Google Scholar
• Lister MF, Sharkey J, Sawatzky DA, et al. The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond). 2007;4(1):5. doi: 10.1186/1476-9255-4-5
   PubMedGoogle Scholar
• Rathinam VAK, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792–800. doi: 10.1016/j.cell.2016.03.046
   PubMed Web of Science ®Google Scholar
• Khalafalla MG, Woods LT, Camden JM, et al. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy. J Biol Chem. 2017;292(40):16626–16637. doi: 10.1074/jbc.M117.790741
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Gøransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome – a double blind, randomised clinical trial. PloS One. 2012;7:e30123. doi: 10.1371/journal.pone.0030123
   PubMed Web of Science ®Google Scholar
• Gong Y-Z, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. J Autoimmun. 2014;51:57–66. doi: 10.1016/j.jaut.2013.11.003
   PubMed Web of Science ®Google Scholar
• Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021;80(3):329–338. doi: 10.1136/annrheumdis-2020-218467
   PubMed Web of Science ®Google Scholar
• Berry JS, Tarn J, Casement J, et al. Examining the biological pathways underlying clinical heterogeneity in Sjogren’s syndrome: proteomic and network analysis. Ann Rheum Dis. 2024;83(1):88–95. doi: 10.1136/ard-2023-224503
   PubMed Web of Science ®Google Scholar
• Gupta S, Singh RK, Dastidar S, et al. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets. 2008;12(3):291–299. doi: 10.1517/14728222.12.3.291
   PubMed Web of Science ®Google Scholar
• Saegusa K, Ishimaru N, Yanagi K, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002;110(3):361–369. doi: 10.1172/JCI0214682
   PubMed Web of Science ®Google Scholar
• Bentley D, Fisher BA, Barone F, et al. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren’s syndrome. Rheumatology. 2023;kead092(11):3644–3653. doi: 10.1093/rheumatology/kead092
   Google Scholar
• Van Nimwegen JF, Mossel E, Van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2020;2(3):e153–e163. doi: 10.1016/S2665-9913(19)30160-2
   PubMedGoogle Scholar
• Baer AN, Gottenberg J-E, Clair EWS, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheumatic Dis. 2021;80(3):339–348. doi: 10.1136/annrheumdis-2020-218599
   PubMed Web of Science ®Google Scholar
• Arends S, de WL, van NJ, et al. Composite of relevant endpoints for Sjögren’s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2021;3(8):e553–e562. doi: 10.1016/S2665-9913(21)00122-3
   PubMedGoogle Scholar
• Machado AC, dos Santos LC, Fidelix T, et al. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren’s syndrome. Clin Rheumatol. 2020;39(1):243–248. doi: 10.1007/s10067-019-04724-w
   PubMed Web of Science ®Google Scholar
• de Wolff L, van Nimwegen JF, Mossel E, et al. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren’s syndrome: the open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum. 2022;53:151955. doi: 10.1016/j.semarthrit.2022.151955
   PubMed Web of Science ®Google Scholar
• A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sjögren’s syndrome [internet]. ACR Meeting Abstracts. [cited 2023 Oct 4]. Available from: https://acrabstracts.org/abstract/a-phase-2a-study-of-medi5872-amg557-a-fully-human-anti-icos-ligand-monoclonal-antibody-in-patients-with-primary-sjogrens-syndrome/.
   Google Scholar
• Research C for DE and. Efalizumab (marketed as raptiva) information. FDA [Internet]. 2019 [cited 2023 Oct 4]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/efalizumab-marketed-raptiva-information.
   Google Scholar
• Research C for DE and. FDA drug safety communication: safety update on progressive multifocal leukoencephalopathy (PML) associated with tysabri (natalizumab). FDA [Internet]. 2019 [cited 2023 Oct 4]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-progressive-multifocal-leukoencephalopathy-pml.
   Google Scholar
• Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901. doi: 10.1177/1073274817729901
   Web of Science ®Google Scholar
• Bootsma H, Kroese FGM, Vissink A. Editorial: Rituximab in the treatment of Sjögren’s syndrome: is it the right or wrong drug? Arthritis & Rheumat. 2017;69(7):1346–1349. doi: 10.1002/art.40095
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab. Ann Inter Med [Internet]. 2014 [cited 2023 Oct 5]. Available from: https://www.acpjournals.org/doi/10.7326/M13-1085.
   Google Scholar
• Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis & Rheumat. 2017;69(7):1440–1450. doi: 10.1002/art.40093
   PubMed Web of Science ®Google Scholar
• van Nimwegen JF, Moerman RV, Sillevis Smitt N, et al. Safety of treatments for primary Sjögren’s syndrome. Expert Opin Drug Saf. 2016;15(4):513–524. doi: 10.1517/14740338.2016.1146676
   PubMed Web of Science ®Google Scholar
• Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102–110. doi: 10.1016/j.jaut.2015.11.002
   PubMed Web of Science ®Google Scholar
• Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren’s syndrome responder index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology. 2015;54(9):1699–1708. doi: 10.1093/rheumatology/kev114
   PubMed Web of Science ®Google Scholar
• Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjögren’s syndrome. [cited 2023 Oct 5]. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.39088.
   Google Scholar
• Seror R, Baron G, Camus M, et al. Development and preliminary validation of the Sjögren’s tool for assessing response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann Rheumatic Dis. 2022;81(7):979–989. doi: 10.1136/annrheumdis-2021-222054
   PubMed Web of Science ®Google Scholar
• Pontarini E, Sciacca E, Chowdhury F, et al. Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren’s syndrome. Arthritis & Rheumatology [Internet]. [cited 2023 Dec 26].Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.42772.
   Google Scholar
• Nocturne G, Marmontel O, di Filippo M, et al. Efficacy of daratumumab in refractory primary Sjögren disease. RMD Open. 2023;9(3):e003464. doi: 10.1136/rmdopen-2023-003464
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817–826. doi: 10.4049/jimmunol.174.2.817
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32:490–494.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. 2015;54:2249–2256. doi: 10.1093/rheumatology/kev257
   PubMed Web of Science ®Google Scholar
• Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight [Internet]. 2022 [cited 2023 Oct 4]; 7(23). Available from: https://insight.jci.org/articles/view/163030
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399(10320):161–171. doi: 10.1016/S0140-6736(21)02251-0
   PubMed Web of Science ®Google Scholar
• Shi F, Xue R, Zhou X, et al. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666–673. doi: 10.1080/08923973.2021.1973493
   PubMed Web of Science ®Google Scholar
• Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology. 2023;kead265. doi: 10.1093/rheumatology/kead265
   PubMedGoogle Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283–294. doi: 10.1038/nri3823
   PubMed Web of Science ®Google Scholar
• Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome. Ann Rheumatic Dis. 2018;77(12):1838–1840. doi: 10.1136/annrheumdis-2018-213036
   PubMed Web of Science ®Google Scholar
• He J, Chen J, Miao M, et al. Efficacy and safety of low-dose interleukin 2 for primary Sjogren syndrome: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241451. doi: 10.1001/jamanetworkopen.2022.41451
   PubMed Web of Science ®Google Scholar
• Fava RA, Kennedy SM, Wood SG, et al. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren’s syndrome. Arthritis Res Ther. 2011;13(6):R182. doi: 10.1186/ar3507
   PubMed Web of Science ®Google Scholar
• EW SC, Baer AN, Wei C, et al. Clinical efficacy and safety of baminercept, a lymphotoxin β receptor fusion protein, in primary Sjögren’s syndrome. Arthritis & Rheumatology. 2018;70(9):1470–1480. doi: 10.1002/art.40513
   PubMed Web of Science ®Google Scholar
• Gatumu MK, Skarstein K, Papandile A, et al. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther. 2009;11(1):R24. doi: 10.1186/ar2617
   PubMed Web of Science ®Google Scholar
• Haskett S, Ding J, Zhang W, et al. Identification of novel CD4+ T cell subsets in the target tissue of Sjögren’s syndrome and their differential regulation by the lymphotoxin/light signaling axis. J Immunol. 2016;197(10):3806–3819. doi: 10.4049/jimmunol.1600407
   PubMed Web of Science ®Google Scholar
• Ridgewell D, Thalayasingam N, Ng W-F. Sjögren’s syndrome: shedding light on emerging and key drug targets. Expert Opin Ther Targets. 2022;26(10):869–882. doi: 10.1080/14728222.2022.2157259
   PubMed Web of Science ®Google Scholar
• Karageorgas T, Fragioudaki S, Nezos A, et al. Fatigue in primary Sjögren’s syndrome: clinical, laboratory, psychometric, and biologic associations. Arthritis Care Res (Hoboken). 2016;68(1):123–131. doi: 10.1002/acr.22720
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis & rheumat. 2017;69(1):35–45. doi: 10.1002/art.39859
   PubMed Web of Science ®Google Scholar
• Vissink A, Bootsma H. Connective tissue diseases: refining the classification criteria for primary Sjogren syndrome. Nat Rev Rheumatol. 2016;13(1):10–12. doi: 10.1038/nrrheum.2016.208
   PubMedGoogle Scholar
• Tarn JR, Howard-Tripp N, Lendrem DW, et al. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019;1(2):e85–e94. doi: 10.1016/S2665-9913(19)30042-6
   PubMedGoogle Scholar
• Martin-Gutierrez L, Peng J, Thompson NL, et al. Stratification of patients with Sjögren’s syndrome and patients with systemic lupus erythematosus according to two shared immune cell signatures, with potential therapeutic implications. Arthritis & rheumat. 2021;73(9):1626–1637. doi: 10.1002/art.41708
   PubMed Web of Science ®Google Scholar
• Altman J, Jones G, Ahmed S, et al. Tear film MicroRNAs as potential biomarkers: a review. Int J Mol Sci. 2023;24(4):3694. doi: 10.3390/ijms24043694
   PubMed Web of Science ®Google Scholar
• Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–389. doi: 10.1136/annrheumdis-2014-206008
   PubMed Web of Science ®Google Scholar
• Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases. Trends Pharmacol Sci. 2023;44(7):411–424. doi: 10.1016/j.tips.2023.04.005
   PubMedGoogle Scholar
• Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet [Internet]. 2023; [cited 2023 Sep 26]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01126-1/fulltext
   Google Scholar
• de Buys P, Khanna D, Furst DE. Hemopoietic stem cell transplantation in rheumatic diseases—an update. Autoimmun Rev. 2005;4(7):442–449. doi: 10.1016/j.autrev.2005.03.003
   PubMed Web of Science ®Google Scholar